References
- 1. Terwee CB, Dekker FW, Mourits MP, Gerding MN, Baldeschi L, Kalmann R, et al. Interpretation and validity of changes in scores on the Graves’ ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments. Clin Endocrinol (Oxf). 2001; 54:391-8.10.1046/j.1365-2265.2001.01241.x
- 2. Wall JR and Lahooti H. Pathogenesis of thyroid eye disease-does autoimmunity against the TSH receptor explain all cases? Endokrynol Pol. 2010; 61:222-7.
- 3. Lahooti H, Parmar KR, and Wall JR. Pathogenesis of thyroid-associated ophthalmopathy: does autoimmunity against calsequestrin and collagen XIII play a role? Clin Ophthalmol. 2010; 4:417-25.
- 4. Dittmar M and Kahaly GJ. Immunoregulatory and susceptibility genes in thyroid and polyglandular autoimmunity. Thyroid. 2005; 15:239-50.10.1089/thy.2005.15.239
- 5. Weetman AP. Graves’ disease. N Engl J Med. 2000; 343:1236-48.10.1056/NEJM200010263431707
- 6. Pappa A, Lawson JM, Calder V, Fells P, and Lightman S. T cells and fibroblasts in affected extraocular muscles in early and late thyroid associated ophthalmopathy. Br J Ophthalmol. 2000; 84:517-22.10.1136/bjo.84.5.517
- 7. Chavis PS. Thyroid and the eye. Curr Opin Ophthalmol. 2002; 13:352-6.10.1097/00055735-200212000-00002
- 8. Krassas GE. Octreoscan in thyroid-associated ophthalmopathy. Thyroid. 2002; 12:229-31.10.1089/105072502753600188
- 9. Galuska L, Varga J, Farkas ZS, Garai I, Boda J, Szabo J, et al. Active retrobulbar inflammation in Graves’ ophthalmopathy visualized by Tc-99m DTPA SPECT. Clin Nucl Med. 2003; 28:515-6.10.1097/01.RLU.0000067520.87766.B6
- 10. Galuska L, Leovey A, Szucs-Farkas Z, Szabados L, Garai I, Berta A, et al. Imaging of disease activity in Graves’ orbitopathy with different methods: comparison of 99mTc-DTPA and 99mTc-depreotide single photon emission tomography, magnetic resonance imaging and clinical activity scores. Nucl Med Commun. 2005; 26:407-14.10.1097/00006231-200505000-00003
- 11. Galuska L, Leovey A, Szucs-Farkas Z, Garai I, Szabo J, Varga J, et al. SPECT using 99mTc-DTPA for the assessment of disease activity in Graves’ ophthalmopathy: a comparison with the results from MRI. Nucl Med Commun. 2002; 23:1211-6.10.1097/00006231-200212000-00010
- 12. Forster GJ, Krummenauer F, Nickel O, and Kahaly GJ. Somatostatin-receptor scintigraphy in Graves’ disease: reproducibility and variance of orbital activity. Cancer Biother Radiopharm. 2000; 15:517-25.10.1089/cbr.2000.15.517
- 13. Burggasser G, Hurtl I, Hauff W, Lukas J, Greifeneder M, Heydari B, et al. Orbital scintigraphy with the somatostatin receptor tracer 99mTc-P829 in patients with Graves’ disease. J Nucl Med. 2003; 44:1547-55.
- 14. Sun H, Jiang XF, Wang S, Chen HY, Sun J, Li PY, et al. (99m)Tc-HYNIC-TOC scintigraphy in evaluation of active Graves’ ophthalmopathy (GO). Endocrine. 2007; 31:305-10.10.1007/s12020-007-0039-2
- 15. Kirsch E, von Arx G, and Hammer B. Imaging in Graves’ orbitopathy. Orbit. 2009; 28:219-25.